BACKGROUND: C-reactive protein (CRP) represents a promising prognostic variable in patients with sporadic renal cell carcinoma (RCC). It was hypothesized that CRP can improve the prognostic ability of standard RCC-specific mortality (RCC-SM) predictors in patients treated with nephrectomy for all stages of RCC. METHODS: Radical nephrectomy was performed in 314 patients from 2 European centers. Life table, Kaplan-Meier, and Cox regression analyses addressed RCC-SM. Covariates included age, gender, TNM stage, tumor size, Fuhrman grade, and histologic subtype. RESULTS: The median survival of the cohort was 19.9 years. Age ranged from 10 to 77 years. Most patients were male (69%). T-stages were distributed as follows: T1-121 (38.7%), T2-45 (14.4%), T3-140 (44.7%), T4-7 (2.2%). CRP values ranged from 1.0 to 358.0 mg/L (mean 40.9, median 11.0 mg/L). In multivariable analyses, CRP was an independent predictor of RCC-SM (P = .003). The consideration of CRP in the multivariable model increased the predictive accuracy by 3.7% (P < .001). Moreover, the model with CRP performed 2.4% and 4.6% better than the UCLA Integrated Staging System (UISS) at, respectively, 2 and 5 years. CONCLUSIONS: CRP represents an informative predictor of RCC-SM. Its routine use could allow better risk stratification and risk-adjusted follow-up of RCC patients. (c) 2007 American Cancer Society.
BACKGROUND:C-reactive protein (CRP) represents a promising prognostic variable in patients with sporadic renal cell carcinoma (RCC). It was hypothesized that CRP can improve the prognostic ability of standard RCC-specific mortality (RCC-SM) predictors in patients treated with nephrectomy for all stages of RCC. METHODS: Radical nephrectomy was performed in 314 patients from 2 European centers. Life table, Kaplan-Meier, and Cox regression analyses addressed RCC-SM. Covariates included age, gender, TNM stage, tumor size, Fuhrman grade, and histologic subtype. RESULTS: The median survival of the cohort was 19.9 years. Age ranged from 10 to 77 years. Most patients were male (69%). T-stages were distributed as follows: T1-121 (38.7%), T2-45 (14.4%), T3-140 (44.7%), T4-7 (2.2%). CRP values ranged from 1.0 to 358.0 mg/L (mean 40.9, median 11.0 mg/L). In multivariable analyses, CRP was an independent predictor of RCC-SM (P = .003). The consideration of CRP in the multivariable model increased the predictive accuracy by 3.7% (P < .001). Moreover, the model with CRP performed 2.4% and 4.6% better than the UCLA Integrated Staging System (UISS) at, respectively, 2 and 5 years. CONCLUSIONS:CRP represents an informative predictor of RCC-SM. Its routine use could allow better risk stratification and risk-adjusted follow-up of RCC patients. (c) 2007 American Cancer Society.
Authors: Valéria Jósa; Marcin Krzystanek; Tamás Vass; Tamás Lang; Viktória Juhász; Kamilla Szilágyi; Balázs Tihanyi; László Harsányi; Zoltán Szállási; Ferenc Salamon; Zsolt Baranyai Journal: Pathol Oncol Res Date: 2015-03-13 Impact factor: 3.201
Authors: S P K Jagdev; W Gregory; N S Vasudev; P Harnden; S Sim; D Thompson; J Cartledge; P J Selby; R E Banks Journal: Br J Cancer Date: 2010-11-09 Impact factor: 7.640
Authors: S L Wood; M Rogers; D A Cairns; A Paul; D Thompson; N S Vasudev; P J Selby; R E Banks Journal: Br J Cancer Date: 2010-06-08 Impact factor: 7.640
Authors: J-F Rossi; S Négrier; N D James; I Kocak; R Hawkins; H Davis; U Prabhakar; X Qin; P Mulders; B Berns Journal: Br J Cancer Date: 2010-08-31 Impact factor: 7.640